Curasight aktie (CURAS) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kampanj: Kryptovalutor åter glödhett – så kan du handla utan att betala courtage (annons)

Pressmeddelanden från Curasight

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

The exercise period commences for warrants of series TO3 on 4 June 2025

Copenhagen, Denmark, 3 June 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) hereby announces that the exercise price for...

Cision • 03 Jun 17:45

Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 02 Jun 08:15

Completed registration of rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 28 May 17:25

Resolutions of the Annual General Meeting 2025 of Curasight A/S

Copenhagen, Denmark, 28 May 2025 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the...

Cision • 28 May 14:26

Curasight announces outcome in rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 21 May 08:14

Subscription of new shares in the Right Issue 2025 exercised by Curasight management

Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article ...

Cision • 15 May 16:09

Notice of Annual General Meeting 2025

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICK...

Cision • 13 May 17:14

Last day of the subscription period in Curasight’s rights issue of shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 13 May 08:46

Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer

· Appointment of clinical CRO marks further step in progress in development of uTREAT as a potential new therapeutic solution for aggress...

Cision • 07 May 08:06

BioStock: Teckningsperioden för Curasights företrädesemission har inletts

Curasight genomför för närvarande en företrädesemission om 100 miljoner DKK och teckningsperioden avslutas den 16 maj.

Cision • 06 May 14:28

BioStock: Curasight’s rights issue subscription period has commenced

Curasight is currently conducting a DKK 100 million rights issue, with the subscription period closing on May 16.

Cision • 06 May 14:28

THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 02 May 07:30

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 30 April 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnik...

Cision • 30 Apr 12:17

Curasight A/S publishes disclosure document regarding rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 29 Apr 22:22

Annual Report for the fiscal year 2024

Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the...

Cision • 25 Apr 08:47

Interim report Q1 2025

Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 202...

Cision • 25 Apr 08:25

CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 24 Apr 08:30

Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025

Copenhagen, Denmark, 23 April 2025 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held an Extraordinary General Meetin...

Cision • 23 Apr 11:38

BioStock: Curasight strengthens the investor base with Curium and Pentwater

Curasight has announced a rights issue aiming to raise approximately 100 million DKK.

Cision • 11 Apr 08:26

BioStock: Curasight stärker investerarbasen med Curium och Pentwater

Curasight har tillkännagivit en företrädesemission med målsättningen att ta in cirka 100 miljoner DKK.

Cision • 11 Apr 08:26

Notice of Extraordinary General Meeting of Curasight A/S

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) to an Extraordinary...

Cision • 08 Apr 20:42

Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 04 Apr 17:14

Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025

Copenhagen, Denmark, March 26, 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) announces that the Company’s Annual Gener...

Cision • 26 Mar 07:00

BioStock: Curasight caps 2024 with financing push

Reporting the fourth quarter, financing is high on the agenda for danish Curasight.

Cision • 28 Feb 08:07

Year-end report Q4 2024

Business Highlights during the fourth quarter of 2024 · Curasight designates brain cancer as initial indication for uTREAT® · Data from...

Cision • 27 Feb 07:00

Curasight announces an updated financial calendar 2025

Copenhagen, Denmark, 5 February 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announces that the Company’s Annual Gene...

Cision • 05 Feb 09:24

Participation in warrant exercise by Curasight management

Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Art...

Cision • 10 Dec 2024 19:05

Curasight A/S announces outcome of warrant exercise

Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces the outcome of the exe...

Cision • 10 Dec 2024 07:22

SEB maintain valuation range midpoint at DKK 54 per share

Copenhagen, Denmark, 2 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that SEB reiterates a f...

Cision • 02 Dec 2024 08:10

The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024

The 3[rd] of December 2024 is the last day of trading in warrants of series TO2, which were issued in connection with Curasight A/S ("Curasi...

Cision • 02 Dec 2024 07:00

BioStock: Curasights vd reflekterar över starkt Q3

Curasight släppte nyligen sin Q3-rapport, där bolaget konstaterar att man haft bra momentum.

Cision • 26 Nov 2024 08:45

BioStock: Curasight CEO reflects on a Q3 with strong progress

Curasight recently released its Q3 report, reflecting on a period of good momentum.

Cision • 26 Nov 2024 08:45

Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]

· Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming p...

Cision • 22 Nov 2024 08:25

The exercise period for warrants of series TO2 commences today

Copenhagen, Denmark, 21 November 2024 - Today is the first day for the exercise of Curasight A/S’ ("Curasight" or "the Company" - TICKER: CU...

Cision • 21 Nov 2024 07:55

Interim report Q3 2024

Business Highlights during and after the third quarter of 2024 · Curasight designates brain cancer as initial indication for uTREAT · C...

Cision • 21 Nov 2024 07:00

The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share

Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby announces that the exercise pric...

Cision • 20 Nov 2024 08:10

BioStock: Curasight väljer hjärncancer som första indikation för uTREAT

Curasight väljer aggressiv hjärncancer som den första indikationen för uTREAT-behandlingen och planerar att genomföra en kort studie under n...

Cision • 15 Nov 2024 08:45

BioStock: Curasight announces brain cancer as initial target for uTREAT

Brain cancer will be the first indication for Curasight’s uTREAT therapy.

Cision • 15 Nov 2024 08:45

Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference

Copenhagen, Denmark, 14 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasil...

Cision • 14 Nov 2024 07:00

Curasight announces international patent application for uTREAT® to broaden IP protection

· New patent application related to uTREAT will extend patent protection until 2043 · Application adds several new alpha- and beta-emit...

Cision • 13 Nov 2024 07:05

Curasight will present at the BioStock Life Science Summit, November 21

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21.

Cision • 11 Nov 2024 11:00

Curasight presenterar på BioStock Life Science Summit 21 november

Den sjunde upplagan av BioStock Life Science Summit går av stapeln 20-21 november, i Lund.

Cision • 11 Nov 2024 11:00

Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025

· Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT[®] · Addresses a clear unmet medical need · Clinical...

Cision • 11 Nov 2024 07:00

BioStock: Fullständiga fas II-resultat med uPAR-PET i glioblastom publicerade

Curasight har publicerat fullständiga data från en prövarinitierad fas II-studie som utvärderar uTRACE hos hjärncancerpatienter i tidskrifte...

Cision • 08 Nov 2024 14:25

BioStock: Full phase II results of uPAR-PET in glioblastoma published

Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technology in brain cancer...

Cision • 08 Nov 2024 14:25

Curasight to present at Dansk Aktionærforening InvestorDagen

Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasiln...

Cision • 08 Nov 2024 10:42

Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer

· Curasight’s radiopharmaceutical approach leverages the uPAR theranostic platform with the aim of providing improved diagnosis (uTRACE) ...

Cision • 07 Nov 2024 07:00

BioStock: Curasight well-placed in hot radiopharma sector

The radiopharmaceutical sector is gaining considerable momentum as companies increasingly recognize its potential to offer highly targeted c...

Cision • 22 Oct 2024 08:45

BioStock: Curasight väl positionerat inom het radiofarmakasektor

Radiofarmakasektorn är på stark frammarsch. En uppsjö av investeringar, förvärv och partnerskap gör området till ett av de hetaste inom onko...

Cision • 22 Oct 2024 08:45

Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRA...

Cision • 11 Oct 2024 13:19

Curasight A/S rights issue heavily oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 03 Oct 2024 08:41

Commencement of subscription period in Curasight’s preferential rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 16 Sep 2024 08:50

Curasight A/S publishes prospectus due to upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 12 Sep 2024 12:22

BioStock: Curasight carries out the first step of capitalization

In late June, Curasight announced a capital raise package of up to DKK 120 million to finance the ongoing development of its theranostic pla...

Cision • 10 Sep 2024 08:15

BioStock: Curasight genomför första steget i kapitalanskaffning

I slutet av juni tillkännagav Curasight ett kapitalanskaffningspaket på upp till 120 miljoner DKK för att finansiera den pågående utveckling...

Cision • 10 Sep 2024 08:15

The Board of Directors resolves on a directed issue of units and preferential rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 04 Sep 2024 09:25

BioStock: Curasight siktar på kliniskt proof-of-concept för uTREAT

Efter att ha säkrat finansiering för den pågående kliniska utvecklingen av uTRACE kan Curasight nu ta nästa steg i utvecklingen av den terap...

Cision • 29 Aug 2024 08:15

BioStock: Curasight targets clinical proof-of-concept for uTREAT

Having secured financing for the ongoing clinical development of uTRACE, Curasight can now enter the next level in developing the therapeuti...

Cision • 29 Aug 2024 08:15

Interim report Q2 2024

Business Highlights during the second quarter 2024 · Strengthened financial base with funding of DKK 27.

Cision • 22 Aug 2024 07:00

Curasight issues warrants as part of long-term incentive program

Copenhagen, Denmark, 30 July 2024 - Curasight A / S ("Curasight" or the “Company"- TICKER: CURAS) announces today that it has re-issued a to...

Cision • 30 Jul 2024 10:39

Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024

Copenhagen, Denmark, 2 July 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held an Extraordinary General Meeting ...

Cision • 02 Jul 2024 14:11

Directed issues registered at the Danish Business Authority

Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the directed issues de...

Cision • 01 Jul 2024 11:53

BioStock: Curasights vd kommenterar kapitalanskaffning och milstolpe

Curasight har rekryterat den första patienten i sin fas II-studie med uTRACE i prostatacancer, vilket aktiverar en andra betalning på 500 00...

Cision • 25 Jun 2024 09:15

BioStock: Curasight CEO comments on capital raise and milestone

Curasight has enrolled the first patient in its phase II trial with uTRACE in prostate cancer, activating a second USD 500,000 payment from ...

Cision • 25 Jun 2024 09:15

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilniko...

Cision • 22 Jun 2024 11:22

Notice of Extraordinary General Meeting

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting...

Cision • 17 Jun 2024 16:05

Curasight A/S resolves on directed issues and a loan facility

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 14 Jun 2024 17:22

Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer

· Recruitment of first patient triggers second milestone payment of USD 500.

Cision • 12 Jun 2024 07:11

BioStock: Curasight committed to progressing pipeline

The partnership with Curium for diagnosis in prostate cancer is advancing and Curasight aims to accelerate the development of the therapeuti...

Cision • 04 Jun 2024 08:45

BioStock: Curasight tar nästa steg i utvecklingen av pipelinen

Partnerskapet med Curium inom prostatacancer fortskrider och Curasight siktar på att accelerera utvecklingen av den terapeutiska plattformen...

Cision • 04 Jun 2024 08:45

Interim report Q1 2024

Business Highlights during the first quarter 2024 · Announcing the achievement of the first milestone under the agreement with Curium Inc...

Cision • 23 May 2024 07:00

BioStock: Curasight får grönt ljus från EMA för fas II prostatacancerstudie

Partnerskapsavtalet med Curium förra året är Curasights viktigaste milstolpe hittills.

Cision • 22 Apr 2024 08:45

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial

The partnership deal closed with Curium last year marks the most important milestone for Curasight to date.

Cision • 22 Apr 2024 08:45

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Dosing of first patient expected 2Q 2024 · CTA approval marks progress in development of uTRACE[®] in prostate cancer under the colla...

Cision • 16 Apr 2024 20:39

Curasight announces change in the Board of Directors

Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS)  announces that the chairperson of the Board of Di...

Cision • 12 Apr 2024 11:58

Resolutions of the Annual General Meeting 2024 of Curasight A/S

Copenhagen, Denmark, 21 March 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at t...

Cision • 21 Mar 2024 12:30

BioStock: Curasight cancels rights issue and evaluates alternative financing

In mid February, Curasight announced a DKK 51.2 million rights issue to accelerate clinical development of uTREAT and uTRACE.

Cision • 13 Mar 2024 08:15

BioStock: Curasight avbryter emission och utvärderar alternativ finansiering

I mitten av februari tillkännagav Curasight en företrädesemission om 51,2 miljoner DKK för att påskynda den kliniska utvecklingen av uTREAT ...

Cision • 13 Mar 2024 08:15

Curasight not to proceed with rights issue; evaluating alternative financing opportunities

Copenhagen, Denmark, 11 March 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today it will not proceed with t...

Cision • 11 Mar 2024 21:53

Notice of Annual General Meeting 2024

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICK...

Cision • 06 Mar 2024 11:26

The subscription period in Curasight’s rights issue begins today

Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the “Company" –...

Cision • 23 Feb 2024 08:35

Curasight publishes information memorandum in connection with forthcoming rights issue

Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has prepared and published an informati...

Cision • 22 Feb 2024 12:47

Annual Report for the fiscal year 2023

Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for ...

Cision • 22 Feb 2024 08:46

Year-end report October – December 2023

Business Highlights during the fourth quarter 2023 · Encouraging preclinical data using uTREAT in non-small cell lung cancer · Announci...

Cision • 22 Feb 2024 07:00

BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium.

Cision • 19 Feb 2024 08:22

BioStock: Curasight accelererar sin terapeutiska strategi genom att ta in 51,2 MDKK

Curasights 2023 kretsade kring prostatacancer och licensavtalet med Curium.

Cision • 19 Feb 2024 08:22

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of sh...

Cision • 13 Feb 2024 08:13

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic pla...

Cision • 13 Feb 2024 08:11

BioStock: Curasight får första milstolpebetalningen från Curium

Prostatacancersamarbetet med Curium är det hittills viktigaste steget som det radiofarmaceutiska bioteknikbolaget Curasight tagit.

Cision • 02 Feb 2024 08:45

BioStock: Curasight gets first milestone payment from Curium

The prostate cancer partnership with Curium marks the most pivotal moment for the radiopharmaceutical focused biotech company Curasight to d...

Cision • 02 Feb 2024 08:45

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

· USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercializati...

Cision • 22 Jan 2024 07:00

BioStock: Curasight gears up for phase II study in prostate cancer

Following the Curium deal this spring, Curasight has now submitted a clinical trial application and selected a CRO to carry out a phase II t...

Cision • 22 Dec 2023 09:15

BioStock: Curasight förbereder för fas II-studie i prostatacancer

Efter Curium-affären i våras har Curasight nu lämnat in en klinisk prövningsansökan och valt en CRO för att genomföra en fas II-studie med u...

Cision • 22 Dec 2023 09:15

Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Company on track to dose first patient in 2Q 2024 · CTA marks progress in development of uTRACE[®] in prostate cancer under the colla...

Cision • 18 Dec 2023 18:31

Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer

· Phase 2 study is part of the collaboration between Curasight and Curium announced earlier this year · Appointment of clinical CRO mar...

Cision • 13 Dec 2023 17:53

BioStock: Curasights vd: “Arbetar med accelererad plan för uTREAT”

När vi ser tillbaka på det tredje kvartalet är det tydligt att Curasight håller tempot uppe i utvecklingen.

Cision • 28 Nov 2023 09:15

BioStock: Curasight CEO: “Working on accelerated plan for uTREAT”

Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development.

Cision • 28 Nov 2023 09:15

Curasight to present at HC Andersen Capital and Stokk.io

Copenhagen, Denmark, 24 November 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasil...

Cision • 24 Nov 2023 07:00

Interim Report January – September 2023

Business Highlights during the third quarter 2023 · Encouraging preclinical data using uTREAT[®] in non-small cell lung cancer · Positi...

Cision • 23 Nov 2023 07:00

BioStock: Positive preclinical results for Curasight in lung cancer

Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing...

Cision • 20 Oct 2023 09:21